SS-31 (Elamipretide): What the Research Actually Shows

Mitochondrial health gets talked about constantly in the peptide world, and SS-31 (also known as elamipretide) is one of the few compounds in this space with an actual mechanistic story behind that talk, plus real human trial data. That combination makes it worth a careful look, not a hype-driven one.

What SS-31 is

SS-31 is a small synthetic tetrapeptide developed originally at Cornell and later advanced clinically under the name elamipretide. Unlike most research peptides discussed online, it has an unusually specific, well-characterized mechanism: it binds cardiolipin, a lipid found almost exclusively in the inner mitochondrial membrane, and appears to stabilize the folded cristae structure where the electron transport chain does its work. The proposed downstream effects are reduced oxidative stress and more efficient ATP production (Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential).

What's actually been studied

Barth syndrome. A phase 2/3 randomized controlled trial, followed by an open-label extension, examined whether elamipretide improved muscle strength and a submaximal exercise test in patients with Barth syndrome, a rare genetic disorder of mitochondrial cardiolipin metabolism. Neither primary endpoint was met in the randomized portion (Genetics in Medicine, 2021).
Primary mitochondrial myopathy. The MMPOWER-3 randomized clinical trial examined elamipretide against a six-minute walk test and a patient-reported fatigue scale in adults with primary mitochondrial myopathy. It did not meet its primary endpoints on either measure (Neurology, 2023).
Heart failure. The PROGRESS-HF phase 2 trial tested elamipretide in patients with heart failure with reduced ejection fraction, looking at change in left ventricular end-systolic volume. It did not significantly improve that primary endpoint compared with placebo (Journal of Cardiac Failure, 2020).
Aging mitochondria (animal and cell-model work). Separate mechanistic studies in aged rodent mitochondria report that SS-31 improves ADP sensitivity by increasing uptake through the adenine nucleotide translocator, a transport protein central to ATP export (PubMed, 2023). A mouse model of Barth syndrome similarly showed improved cardiac mitochondrial morphology and mitophagy after SS-31 treatment (Scientific Reports, 2024).

Where the evidence is thin

This is the unusual case where a research peptide has more human trial data than animal data, and the human data has been consistently disappointing on primary endpoints. Three separate randomized trials, across three different conditions (Barth syndrome, primary mitochondrial myopathy, and heart failure), failed to hit their primary endpoints. That's a meaningfully different evidence picture than a compound that simply hasn't been tested in humans yet: this one has been tested, repeatedly, in well-designed trials, and hasn't delivered the result it was tested for. Reported side effects in these trials were mostly injection-site reactions (redness, itching, pain), generally described as mild. None of this means the mitochondrial mechanism is wrong. It means that a plausible mechanism has not yet translated into a trial hitting its own predefined endpoint, which is exactly the gap forum discussions tend to skip over.

The regulatory picture

Elamipretide is not FDA-approved for any condition. It has been studied under expanded access and clinical trial programs for specific rare diseases, but that is not the same as marketing approval, and none of the trials above changed that status. It's sold by research chemical vendors strictly for laboratory research, not for human use.

Papa's take

I don't think SS-31 is a case of "no real science," the mechanism and the trial pipeline are both real, and that alone puts it ahead of a lot of what gets hyped in this space. But I also don't think the online enthusiasm around it reflects the actual trial record, which is three primary-endpoint misses in a row across different patient populations. If you're researching mitochondrial-health peptides, this is a good example of why "there's a clinical trial for it" and "the clinical trial worked" are two different claims, and only reading the abstract's conclusion sentence instead of the actual results section is how those two claims get blurred.

Sources

Sourcing for research

If you're sourcing SS-31 for laboratory research, purity documentation matters. See my vendor comparisons for how I evaluate third-party certificates of analysis.